Skip to main
  1. Stocks
  2. NRX Pharmaceuticals
  3. Forecast
NRXP

NRX Pharmaceuticals (NRXP) Stock Forecast & Price Target

NRX Pharmaceuticals (NRXP) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NRX Pharmaceuticals is supported by a meaningful regulatory inflection after FDA approval of KETAFREE, a preservative-free, U.S.-manufactured ketamine product that addresses the benzethonium chloride issue and can leverage proprietary blow-fill-seal packaging. The company is transitioning from clinical-stage to commercial stage with about 5 million launch units in process and anticipated capacity of 1 million units per month, while management’s 2026 revenue estimate of $5 million and 2027 estimate of $60 million appears conservative relative to the launch potential. Its larger upside thesis rests on NRX-100 and NRX-101, which target bipolar depression with suicidality in a market with no approved medicine, backed by existing clinical data, FDA filing progress, and potential approvals in 2027.

Bears say

NRX Pharmaceuticals is a clinical-stage developer with a fragile financial profile, as its Q2 2026 revenue was only $1.1 million versus expectations of $3.0 million to $16.6 million, underscoring weak commercialization and limited near-term operating traction. The company’s $16.5 million net loss, or $(0.44) per share, also came in worse than the $(0.13) to $0.06 range, highlighting continued cash burn and poor earnings visibility. With no company guidance and only nascent HOPE business revenue beginning in Q3 2025, the fundamental case remains challenged by high execution risk and a still-developing revenue base.

NRX Pharmaceuticals (NRXP) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NRX Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

NRX Pharmaceuticals (NRXP) Analyst Forecast & Price Prediction

Get the latest NRX Pharmaceuticals (NRXP) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in NRX Pharmaceuticals (NRXP)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NRX Pharmaceuticals (NRXP) Forecast

Analysts have given NRX Pharmaceuticals (NRXP) a Strong Buy based on their latest research and market trends.

According to 4 analysts, NRX Pharmaceuticals (NRXP) has a Strong Buy consensus rating as of Nov 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NRX Pharmaceuticals (NRXP)


NRX Pharmaceuticals (NRXP) Analyst Forecast & Price Prediction

Get the latest NRX Pharmaceuticals (NRXP) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in NRX Pharmaceuticals (NRXP)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover NRXP stock data and trends